Tag : relapse of multiple sclerosis

Neurology

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed

Newsemia
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of...
Neurology

B Cell Test Predicts Alemtuzumab Autoimmunity in MS

Newsemia
Analyzing B cell counts before treatment could help select patients for the drug, a new study suggests. Medscape Medical News Source link...
Neurology

Masitinib Impresses in 'Nonactive' Progressive MS

Newsemia
The drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary progressive forms of the disease, where...
Neurology

Lowering Rituximab Dose in Patients With MS Safe, Effective

Newsemia
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and...
Neurology

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

Newsemia
The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis. FDA Approvals Source link...
Neurology

PRAC Restricts Use of Alemtuzumab for MS Pending Ongoing Review

Newsemia
The EMA committee recommends updating the product information to note the potential for acute immune-mediated conditions, stroke, cervicocephalic arterial dissection, and severe neutropenia. News Alerts...
Neurology

MS Linked to Alterations in Bile Acid Metabolism

Newsemia
Abnormalities of these cholesterol metabolites in both children and adults with MS, along with encouraging preclinical findings, have spurred a clinical trial to assess supplementation...
Neurology

Novel Anti-B-Cell Therapy Looks Promising in MS

Newsemia
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study....
Neurology

Years of Thyroid Monitoring Needed After MS Drug Alemtuzumab

Newsemia
New study shows fluctuating patterns of thyroid dysfunction and later onset than previously seen associated with the MS drug alemtuzumab, suggesting the need for ongoing...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World